Inbeeo’s Post

Why doesn't scientific research evolve as a solution to problems in Brazil? The answers to this question go through several layers and one of them is the importance of the intersection between the public sector and the private sector in building partnerships in both the development and regulation of processes. Who highlights this is Marina Domenech, CEO of Intrials Clinical Research, founder of SAIL for Health and vice-president of the Brazilian Association of Representative Organizations for Clinical Research (ABRACRO). She also states that having Biotimize and a #CDMO in Brazil means being able to scale research and retain technology within the country, avoiding the diaspora of knowledge to reach full innovation. This is a fundamental step towards strengthening the health ecosystem, allowing Brazil to become increasingly self-sufficient in scientific development and expanding the population's access to quality healthcare. #FromPaperToThePeople is a series of content about the importance of infrastructure for scaling research, allowing it to get off the ground and reach those in need. #Sthorm #FindTheOthers #Biotechnology #Biotimize #People #Research #FutureofHealthCare

Yesterday at the #NordicFutureHealth2024, Ulrika Morris, PhD presented her work within the Biobank Sweden Cohort Project. In short: Swedish biobank cohorts are a gold mine for medical research, used in some 300-400 publications annually. The key step to access these resources are similar across cohorts and you can find more information at biobanksverige.se. However, there are certain issues that biobank cohorts are battling, such as increased legal complexity of sample and data sharing, precuring long-term funding, and the need to ensure their continued use in research. Suggested changes to national legislation might help to some extent. Could the European Health Data Space (EHDS) be a saviour in part? #NordicFutureHealth2024 #research #cohort #biobanking #EHDS #biobank #PrecisionMedicine #PrecisionHealth Biobank Norway NSHG-PM

Why doesn’t scientific research evolve as a solution to problems in Brazil? This was one of the main topics at the 5th National Science, Technology and Innovation Conference, held in Brasília last week and lead by Ministério da Ciência, Tecnologia e Inovação. Participating in this discussion and bringing solutions like Biotimize’s to standardize regulatory processes with a view to scaling and, consequently, advances in clinical trials is a huge step towards achieving innovation in the healthcare area. In addition to being alongside Carolini Kaid (VYROBIO), Fernando César Barbosa (Biotimize) and Norberto Prestes (ABIQUIFI) we spoke with the Director of the National Health Surveillance Agency (ANVISA), Meiruze Freitas. She highlights that “Our duty today is to bring a regulatory control and a standard to get closer to what is happening in universities and startups, in order to effectively transform it into benefits to our country, whether by promoting more research or by transforming these products into social value and added value, in addition to boosting our economy.” #FromPaperToThePeople is a series of talks about the importance of infrastructure for scaling research, allowing it to get off the ground and reach those in need. #Sthorm #FindTheOthers #Biotechnology #Biotimize #People #ANVISA

March 27, 9am PT. This month, we’re discussing innovation in the realm of rare diseases. Join 2023-25 Policy Fellow, Erika Modina, as she moderates a conversation on the Inflation Reduction Act and the Orphan Cures Act featuring Policy Analyst Mason Barrett of the National Organization for Rare Disorders, Jon Brodo, Policy Director of the Todd Strategy Group, and Cartier Esham, Chief Scientific Officer of the Biotechnology Innovation Organization. How do the two legislative efforts intersect? And what could their impact be on the delicate balance between innovation, affordability, and access as it relates to rare diseases? Registration link in the comments #healthpolicy #healthtech #biotech #rarediseases

Few researchers and organisations have the expertise, skills, and infrastructure to tackle #AMR and discover new #antibiotics. Long-term funding for #antibiotic development partnerships will help attract young scientists to the field and keep companies in anti-infective drug development. To secure a sustainable future for efforts of this scale, we call on government leaders, the private sector and other stakeholders to invest in the development of antibiotics and AMR research.   The AMR Accelerator is an Innovative Health Initiative (IHI) programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building #antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of our assets, infrastructures and expertise. Read more in our article: https://lnkd.in/eqGbRqmg Explore our results: https://lnkd.in/ebSUbVhB

🎬 Learn more about BioAlps - Life Sciences Cluster 🇨🇭 in the latest instalment of Greater Geneva Bern area (GGBa) "WHAT IS" series!

Why doesn’t scientific research evolve as a solution to problems in Brazil? This answer even has a famous term among researchers: The Valley of Death - a limbo where scientific research in the health area stagnates and does not advance to reach the clinical testing phases. The person who explains this is Cristiano Gonçalves, Director of Innovation and Technological Licensing at Instituto Butantan. Given this scenario, Cristiano mentions the importance of the role of Biotimize, a startup in the Sthorm health hub, which recently opened a pioneering development complex operating in the “as a service” model (CDMO) under conditions of Good Laboratory Practices ( BPL), this means building a bridge over this valley so that research can develop within the country and reach the pre-clinical phase. #FromPaperToThePeople is a series of content about the importance of infrastructure for scaling research, allowing it to get off the ground and reach those in need. #Sthorm #FindTheOthers #Biotechnology #Biotimize #HeathcareSystem

Join us to experience how #Albio can help to speed up emergency professionals' decision making for patients in dire circumstances and ultimately improving patients' conditions. #EUSEM2024 #Albio #PALFinland   See you there!

Exploring the mode of action of #prebiotics to drive innovation. 🌱 Prebiotics are non-digestible compounds that support beneficial gut microbiota. They are increasingly recognized for their potential to improve health and well-being. Our Prebiotics Task Force is dedicated to advancing the understanding of how these compounds work and their connection to individual health benefits. Upcoming Activities: · Evaluating the potential of New Approach Methodologies (NAMs) to uncover the mechanisms of action of prebiotics and identify new opportunities (in collaboration with the NAMs Task Force). · Identifying key markers to assess gut microbiota improvement, focusing on measurable indicators of microbiota composition (in collaboration with the Probiotics Task Force). By collaborating with leading experts, your organization can play a vital role in shaping the future of prebiotics research and their contribution to health innovation. Join the Prebiotics Task Force today and ensure your voice is part of this vital conversation. 📧 For more info or to get involved, contact Georgia Chatonidi at gchatonidi@ilsieurope.be 👉 Learn more: https://lnkd.in/eZyiXMXn #Prebiotics #GutHealth #Microbiome #Research #CollaborativeScience 

Exploring Baricitinib : Applications, Advantages & Mechanisms https://lnkd.in/d6SwWDhZ #Baricitinib #BaricitinibImpurities #SimsonPharma #Blog #BaricitinibApplications